Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
基本信息
- 批准号:8425740
- 负责人:
- 金额:$ 7.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAmphotericin BAnimal ModelAntibioticsAntibodiesAntibody FormationAntibody TherapyAntifungal AgentsAntifungal TherapyAntigensAutoimmune DiseasesAzolesBiologicalBiological ProductsBirth WeightCandida albicansCandidiasisChemosensitizationClinicComorbidityDataDevelopmentDiseaseDisseminated candidiasisDrug or ChemicalGestational AgeGram-Negative BacteriaGrantHealth Care CostsHospital EconomicsHost DefenseHumanHybridomasImmune systemImmunodominant AntigensIn VitroInfectionInnovative TherapyLeadLength of StayLifeMedicalMethodologyModelingMonoclonal AntibodiesMorbidity - disease rateMusMycosesNeonatalNeurodevelopmental ImpairmentOrgan SurvivalPaperPatientsPharmaceutical PreparationsPremature InfantPreparationResistanceResistance developmentRiskRoleSeminalSerumSpecificitySurfaceTechnologyThe science of MycologyVariantVery Low Birth Weight Infantbasecancer therapychemotherapycombateconomic costin vivoinfectious disease treatmentinterestlarge scale productionmortalityneonatenovelpreventprotective effectpublic health relevancepupresearch studysmall molecule
项目摘要
DESCRIPTION (provided by applicant): Candidiasis represents the most common fungal infection in hospitalized patients and Candida albicans remains the main etiologic agent of candidiasis, as this otherwise normal commensal of humans is capable of causing life-threatening infections in an expanding spectrum of immunocompromissed patients. Neonates, and in particular very low birth weight (VLBW) infants, are highly susceptible to candidiasis, mostly due to their immature immune system; and this risk increases with decreasing birth weight and gestational age. In fact, candidiasis represents now the second most common infection in VLBW neonates. Of note, these infections carry unacceptably high mortality rates (about 45% despite antifungal treatment), double than those associated with infections due to gram positive and gram negative bacteria. Neonatal candidiasis also adds incremental co-morbidity (i.e. neurodevelopmental impairment), length of hospital stay and economic costs. Clearly, these high mortality rates indicate that current antifungal therapy is still ineffective, ue mainly to the limited arsenal of antifungal drugs and the emergence of resistance to most classes of antifungals. These difficulties encountered in the treatment of candidiasis, including i neonates, have led to an increased interest in the search for innovative therapies. Antibody therapy constitutes a very attractive alternative to classical treatment using "small molecule" or "chemical" drugs. In the field of Medical Mycology, seminal papers by the Casadevall group led to a reappraisal of the role of antibodies and a revived interest in the development of antibody-based therapies for the treatment of fungal infections. Despite the fact that the role of antibody response in host defense against candidiasis remains controversial, recently it has been conclusively demonstrated that passive administration of monoclonal antibodies (Mabs) contributes to protection during disseminated candidiasis in relevant animal models. Our main hypothesis is that the development of Mabs will increase the treatment options against candidiasis, with special emphasis on neonatal candidiasis. By virtue of their biological activities, including preliminary data indicating their protective effect in an animal model of infection, we have identified three very promising Mabs (3H3, 1H4 and C7) which serve as the basis of this proposal. Thus, experiments in this small grant will further advance these Mabs as candidates for the development of new biologics for the antibody-therapy of neonatal candidiasis; for which we will i) determine their efficacy in passive transfer of protection (serum
therapy) experiments using a novel murine model of invasive candidiasis in neonates, and ii) determine the in vitro and in vivo efficacy of combinations between these Mabs and clinically used antifungal drugs.
描述(由申请方提供):念珠菌病是住院患者中最常见的真菌感染,白色念珠菌仍然是念珠菌病的主要病原体,因为这种人类正常的念珠菌能够在越来越多的免疫功能低下患者中引起危及生命的感染。新生儿,特别是极低出生体重(VLBW)婴儿,非常容易感染念珠菌病,主要是由于他们的免疫系统不成熟;这种风险随着出生体重和胎龄的降低而增加。事实上,念珠菌病现在是VLBW新生儿的第二大常见感染。值得注意的是,这些感染具有不可接受的高死亡率(尽管进行了抗真菌治疗,仍约为45%),是革兰氏阳性菌和革兰氏阴性菌感染相关死亡率的两倍。新生儿念珠菌病还增加了并发症(即神经发育障碍)、住院时间和经济成本。显然,这些高死亡率表明,目前的抗真菌治疗仍然是无效的,主要是由于有限的抗真菌药物库和出现耐药性的大多数类别的抗真菌药物。在治疗念珠菌病(包括新生儿)中遇到的这些困难导致人们对寻找创新疗法的兴趣增加。抗体疗法构成了使用“小分子”或“化学”药物的经典治疗的非常有吸引力的替代方案。在医学真菌学领域,Casadevall小组的开创性论文导致了对抗体作用的重新评估,并重新引起了人们对开发基于抗体的治疗真菌感染的疗法的兴趣。尽管抗体应答在宿主防御念珠菌病中的作用仍存在争议,但最近已最终证明,被动给予单克隆抗体(Mab)有助于在相关动物模型中的播散性念珠菌病期间提供保护。我们的主要假设是,单克隆抗体的发展将增加对念珠菌病的治疗选择,特别是对新生儿念珠菌病。由于它们的生物活性,包括表明它们在感染动物模型中的保护作用的初步数据,我们已经鉴定了三种非常有前途的单克隆抗体(3 H3、1H 4和C7),它们作为本提议的基础。因此,这项小额资助的实验将进一步推进这些单克隆抗体作为开发新生儿念珠菌病抗体治疗新生物制剂的候选物;为此,我们将i)确定它们在保护(血清)被动转移中的功效。
治疗)实验,和ii)确定这些Mab和临床使用的抗真菌药物之间的组合的体外和体内功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose L. Lopez-Ribot其他文献
Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities
- DOI:
10.1186/s13104-019-4813-z - 发表时间:
2019-11-27 - 期刊:
- 影响因子:1.700
- 作者:
Roberto Vazquez-Muñoz;M. Josefina Arellano-Jimenez;Fernando D. Lopez;Jose L. Lopez-Ribot - 通讯作者:
Jose L. Lopez-Ribot
Fungal biofilms in human health and disease
人类健康与疾病中的真菌生物膜
- DOI:
10.1038/s41579-025-01147-0 - 发表时间:
2025-02-05 - 期刊:
- 影响因子:103.300
- 作者:
Gordon Ramage;Ryan Kean;Riina Rautemaa-Richardson;Craig Williams;Jose L. Lopez-Ribot - 通讯作者:
Jose L. Lopez-Ribot
Antifungal therapy of emCandida/em biofilms: Past, present and future
念珠菌生物膜的抗真菌治疗:过去、现在和未来
- DOI:
10.1016/j.bioflm.2023.100126 - 发表时间:
2023-12-01 - 期刊:
- 影响因子:4.900
- 作者:
Olabayo H. Ajetunmobi;Hamid Badali;Jesus A. Romo;Gordon Ramage;Jose L. Lopez-Ribot - 通讯作者:
Jose L. Lopez-Ribot
Jose L. Lopez-Ribot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose L. Lopez-Ribot', 18)}}的其他基金
High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris
疟疾药物的高通量筛选帮助化学库鉴定新型耳念珠菌抑制剂
- 批准号:
10383652 - 财政年份:2021
- 资助金额:
$ 7.35万 - 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
- 批准号:
10335279 - 财政年份:2019
- 资助金额:
$ 7.35万 - 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
- 批准号:
10320258 - 财政年份:2019
- 资助金额:
$ 7.35万 - 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
- 批准号:
10544529 - 财政年份:2019
- 资助金额:
$ 7.35万 - 项目类别:
Development of novel chemical series of Candida albicans biofilm inhibitors
白色念珠菌生物膜抑制剂新型化学系列的开发
- 批准号:
8951343 - 财政年份:2015
- 资助金额:
$ 7.35万 - 项目类别:
Targeting virulence against oral candidiasis in HIV/AIDS
针对艾滋病毒/艾滋病口腔念珠菌病的毒力
- 批准号:
9234520 - 财政年份:2013
- 资助金额:
$ 7.35万 - 项目类别:
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
- 批准号:
8719015 - 财政年份:2013
- 资助金额:
$ 7.35万 - 项目类别:
Targeting virulence against oral candidiasis in HIV/AIDS
针对艾滋病毒/艾滋病口腔念珠菌病的毒力
- 批准号:
8542240 - 财政年份:2013
- 资助金额:
$ 7.35万 - 项目类别:
相似海外基金
有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
- 批准号:
24K17671 - 财政年份:2024
- 资助金额:
$ 7.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
- 批准号:
MR/X014010/1 - 财政年份:2023
- 资助金额:
$ 7.35万 - 项目类别:
Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2022
- 资助金额:
$ 7.35万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
- 批准号:
22K05333 - 财政年份:2022
- 资助金额:
$ 7.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2021
- 资助金额:
$ 7.35万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10024667 - 财政年份:2020
- 资助金额:
$ 7.35万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
9909193 - 财政年份:2020
- 资助金额:
$ 7.35万 - 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10248529 - 财政年份:2020
- 资助金额:
$ 7.35万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10484014 - 财政年份:2020
- 资助金额:
$ 7.35万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10654834 - 财政年份:2020
- 资助金额:
$ 7.35万 - 项目类别: